News - Townsend Investments
LATEST NEWS:
8th June 2016 - NovaBiotics Presents Three New Posters on Anti-Infectives Pipeline at 39th European Cystic Fibrosis Society Conference

NovaBiotics announces today that three sets of new data will be presented at this year’s European Cystic Fibrosis (CF) Society Conference, taking place in Basel, Switzerland between 8-11 June.

The posters are focused on NovaBiotics’ first-in-class orphan drug candidate Lynovex® (cysteamine), a novel, highly differentiated therapy for the treatment of CF-associated lung disease and Novamycin®, the Company’s first in class antifungal peptide being developed to target life threatening infections, including respiratory fungal infections associated with CF and respiratory aspergillosis.

The presenters are Dr Douglas Fraser-Pitt, Principal Scientist and Research Associates Dan Smith and Dr Laura Katvars at NovaBiotics.

The details of the posters are as follows:

Title: Cysteamine as a strategy against Burkholderia cepacia complex
Poster number: ePS06.2
Presenter: Dan Smith
Date: 9 June 2016
Location: ePoster Corner A
Time: 14.00-15.00

Title: Novel approaches for cystic fibrosis associated respiratory fungal infections
Poster number: ePS03.9
Presenter:  Dr Laura Katvars
Date: 9 June 2016
Location: ePoster Corner A
Time: 14.00–15.00

Title: Inhaled cysteamine for the chronic management and symptomatic control of cystic fibrosis associated lung disease
Poster number: ePS03.5
Presenter: Dr Douglas Fraser-Pitt, Principal Scientist, NovaBiotics
Date: 10 June 2016
Location: ePoster Corner A
Time: 14.00 – 15.00



Go Back